Cellino

🧬 #AI is accelerating drug discovery, but manufacturing remains one of the key challenges in #biotech. What will it take to deliver personalized cell therapies to patients at scale? Our Co-Founder & CEO, Dr. Nabiha Saklayen, joined Galaxy Balance podcast host Cory Smith to share how Cellino is building closed, automated, #AI-driven systems and the role infrastructure plays in expanding patient access to personalized regenerative medicines. 🎧 Listen to the full episode: https://lnkd.in/gzgYQa5X #CellTherapy #RegenMed #AI #Longevity #Bioengineering #Cellino

🧬 How might artificial intelligence reshape the discovery, development, and delivery of #regenerativemedicine therapies? A new publication from NASEM Health & Medicine outlines how #AI is advancing the field, improving trial design in small patient populations and enabling more efficient, scalable manufacturing. The publication features contributions from Dr. Nabiha Saklayen, our Co-Founder & CEO, who serves as a NASEM Committee Co-Chair for the #RegenMedForum. 📄 Check out the publication here: https://lnkd.in/d5VuyYjV #RegenMed #AIinHealth #Biomanufacturing #HealthInnovation #CellinoBio

🧬 Join us next month at #SynBioBeta2026 as our Co-Founder & CEO, Dr. Nabiha Saklayen, speaks on “Epigenetics and Stem Cells Reprogramming / Evidence Based Longevity” on May 7 at 3:30 PM PDT. This discussion will explore how we rewrite the aging program at the cellular level and what it means for the future of #regenerativemedicine and #longevity. Panelists include: 🔹 Dr. Nabiha Saklayen, Co-Founder & CEO, Cellino 🔹 Juliette Humer, Founder & CEO, Muse Bio 🔹 Clarice D. Aiello, Chair of the Board, Quantum Biology Institute 🔹 Anastasia Shindyapina, Team Lead, Retro Biosciences Moderator: 🎤 Rimma Boshernitsan, CEO, DIALOGUE Register here: https://lnkd.in/gHQZYevp SynBioBeta #RegenMed #HealthInnovation #FutureOfMedicine #Cellino

🔬 Join us at the 2026 NOVA | Neuroscience of Vitality and Aging Conference for the “Repair and Regeneration Panel” on April 25 in #Boston, MA. Dr. Nabiha Saklayen, our Co-Founder & CEO, will join industry leaders on the mainstage to discuss how emerging technologies are advancing new approaches to treating age-related #neurologicalconditions. Panelists include: 🔹 Jean Hebert, Advanced Research Projects Agency for Health (ARPA-H) 🔹 Parastoo Khoshakhlagh, Ph.D., GC Therapeutics 🔹 Mark Tomishima, BlueRock Therapeutics Learn more and register: novaneuro.org #Biotech #RegenMed #CellTherapy #AI #PersonalizedMedicine #CellinoBio

Great to see Cellino recognized on Fast Company’s 2026 Most Innovative Biotech list, ranking #8. A strong acknowledgment of the team’s work building scalable cell therapy manufacturing and helping unlock the potential of regenerative medicine.

Excited to share a closer look at the first results from our collaboration with Polyphron! Cellino manufactured four clonal #iPSC lines from demographically diverse donors using its FDA AMT-designated automated optical bioprocess. Polyphron differentiated all four lines into 3D neural tissue and used its closed-loop optimization platform to engineer a key structural feature to defined tolerances across every genetic background. All in less than 90 days from the start of the collaboration. Congratulations to Fabio Boniolo, Matthew Osman, and the Polyphron team, and to Catherine Pilsmaker from our team for leading this important work. 👉 Read the full release: https://lnkd.in/gGW7fZTd 📄 Access the white paper: https://lnkd.in/grHJDfQ2 #CellinoBio #Polyphron #RegenMed #iPSC #PersonalizedMedicine

We’re proud to publish our cross-donor tissue engineering results with Polyphron, demonstrating reproducible tissue manufacturing across genetically diverse patient lines. Cellino manufactured four clonal iPSC lines using our FDA AMT-designated automated optical bioprocess. Polyphron differentiated all four into 3D neural tissue and used its closed-loop optimization platform to engineer a key structural feature to defined tolerances across every genetic background. Despite over 2,000 differentially expressed genes between lines at baseline, the platform converged on high-performing tissue in all cases. 📄 Read the full release: https://lnkd.in/gGW7fZTd #CellinoBio #Polyphron #RegenMed #iPSC #PersonalizedMedicine

The NYSE trading floor lit up with Cellino this week! ✨ A moment that reflects an exciting milestone for our team. We’re proud to be named one of Fast Company’s World’s Most Innovative Companies of 2026. Thank you to the NYSE for celebrating this with us. Read the full release here: https://lnkd.in/gfvurfbh #FCMostInnovative #NYSE #RegenerativeMedicine #CellinoBio

We’re honored to be ranked #8 on Fast Company’s 2026 Most Innovative Companies list in #biotech! 🎉 Cell-based therapies hold enormous potential across many chronic degenerative diseases, but manufacturing personalized treatments has long been complex, time-consuming, and reliant on a small number of experts. Through our closed-loop, #AI-driven platform, we’re enabling more precise, reproducible, and scalable production of patient-specific induced pluripotent stem cells (#iPSCs). 👉 Read the full article: https://lnkd.in/eG_byeKi Thank you, Fast Company, for this recognition as we continue to tackle one of the toughest challenges in #celltherapy manufacturing and unlock broad access to regenerative therapies. #BiotechInnovation #RegenerativeMedicine #FCMostInnovative #CellinoBio

We’re proud to be named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026! 🎉 “Cellino is built on the convergence of AI, biology, and physics to transform how living medicines are delivered at scale,” said Dr. Nabiha Saklayen, CEO & Co-Founder of Cellino As we continue to advance our fully integrated, closed-loop manufacturing platform, our focus remains on enabling scalable, high-quality production of patient-specific induced pluripotent stem cells (#iPSCs) and unlocking broad access to regenerative therapies. We couldn’t be prouder of the team we’ve built and are honored to be recognized alongside other innovators on this list. Read the full release here: https://lnkd.in/gfvurfbh #FCMostInnovative #RegenerativeMedicine #AI #CellTherapy #CellinoBio